HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Reduced effectiveness of Haemophilus influenzae type b conjugate vaccine in children with a high prevalence of human immunodeficiency virus type 1 infection.

AbstractBACKGROUND:
Haemophilus influenzae type b (Hib) conjugate vaccines have successfully reduced the burden of invasive Hib disease in developed countries; however, their effectiveness in countries with a high incidence of pediatric HIV-1 is unknown.
METHODS:
The effectiveness of Hib conjugate vaccine was prospectively evaluated in South African children. The burden of invasive Hib disease in children < 1 year old was compared in 2 cohorts. The first cohort included 22,000 African children born in 1997 [969 (4.45%) of whom were estimated to be HIV-1-infected] who were not vaccinated with Hib conjugate vaccine. This group was compared with 19,267 children [1162 (6.03%) of whom were estimated to be HIV-1 infected] vaccinated at 6, 10 and 14 weeks of age with an Hib conjugate vaccine [TETRAMUNE (polyribosylribitol phosphate-CRM(197)-diphtheria-tetanus toxoids-whole cell pertussis)] between March, 1998, and June, 1999.
RESULTS:
The estimated burden of invasive Hib disease in nonimmunized HIV-1-infected children < 1 year of age was 5.9-fold [95% confidence interval (95% CI), 2.7 to 12.6] higher than in HIV-1-uninfected children. The overall estimated effectiveness of Hib conjugate vaccine in fully vaccinated children <1 year of age was 83.2% (95% CI 60.3 to 92.9). Vaccine effectiveness was significantly reduced in HIV-1-infected [43.9% (95% CI -76.1 to 82.1)] compared with uninfected children [96.5% (95% CI 74.4 to 99.5); P < 10(-5)]. Among three of the fully vaccinated HIV-1-infected children who developed invasive Hib disease, the anti-Hib polyribosylribitol phosphate serum antibody concentrations were 0.23, 0.25 and 0.68 microg/ml.
CONCLUSION:
Although the Hib conjugate vaccine was less effective among HIV-1-infected than among uninfected children, it was 83% effective in preventing overall invasive Hib disease and therefore should be considered for inclusion in the routine vaccination schedule by other African countries.
AuthorsShabir A Madhi, Karen Petersen, Manikant Khoosal, Robin E Huebner, Nontombi Mbelle, Rosalia Mothupi, Haroon Saloojee, Heather Crewe-Brown, Keith P Klugman
JournalThe Pediatric infectious disease journal (Pediatr Infect Dis J) Vol. 21 Issue 4 Pg. 315-21 (Apr 2002) ISSN: 0891-3668 [Print] United States
PMID12075763 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Haemophilus Vaccines
Topics
  • Antibody Formation
  • Cohort Studies
  • Female
  • HIV Infections (complications, immunology)
  • HIV-1 (pathogenicity)
  • Haemophilus Infections (epidemiology, prevention & control, virology)
  • Haemophilus Vaccines (immunology, pharmacology)
  • Haemophilus influenzae type b (immunology, pathogenicity)
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Prevalence
  • Prospective Studies
  • South Africa

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: